SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as the community discusses the potential impact of a recent deal with OpenAI, particularly regarding revenue projections and AMD's position relative to Nvidia. Some believe the deal validates AMD's technology and could drive the share price higher, while others express concerns about valuation and potential overbought conditions. The overall sentiment is bullish, with many anticipating further gains, though some caution a possible pullback is coming.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as the lock-up period expired, leading to a significant drop that some community members believe was overdone, presenting a "buy the dip" opportunity. Discussions revolve around a potential short squeeze, comparisons to similar plays like $HOOD, and the possibility of a reversal to previous levels. Some traders are also looking at options activity and technical indicators to determine potential price movements.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amid discussions around a recent private placement and its potential impact on the stock's future. The community is debating whether this influx of capital will fuel growth or dilute shareholder value, with some highlighting the company's potential in the quantum computing sector while others express concerns about valuation and profitability. Technical analysis and potential government contracts are also being heavily discussed.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals INC ($UPC) is trending due to its low float and strong cash position, leading to speculation about potential buybacks or strategic moves. The community is actively discussing its potential for a short squeeze, drawing comparisons to other recent low-float runners in the biotech sector. Traders are closely watching for news, particularly related to potential cryptocurrency ventures, that could drive further momentum.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market rallies, fueled by optimism around potential rate cuts and continued AI hype, though some community members express concern about a possible bubble. Discussions revolve around the sustainability of the current pump, potential overvaluation, and the influence of government policies. The Invesco QQQ Trust is hitting new all-time highs, prompting debates about market manipulation and whether a significant pullback is on the horizon.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid volatility and debate over its valuation relative to revenue, with discussions focusing on potential catalysts like a possible upcoming offering. Community members are actively debating whether the stock's momentum can be sustained or if a significant pullback is imminent, especially in light of comparisons to other quantum computing companies and broader market conditions. The stock's high trading volume and rapid price appreciation have intensified the discussions.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors discuss its potential as a leader in AI-powered automation, particularly within the agentic economy. Bullish sentiment is fueled by recent partnerships with major players like Nvidia, OpenAI, and Google, sparking speculation about a possible breakout and short squeeze. The community highlights UiPath's strong fundamentals and undervaluation compared to other AI stocks, viewing it as a long-term growth opportunity.

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Xenetic Biosciences Inc

XBIO is trending due to discussions around its low float and potential for a short squeeze, with traders actively pinpointing it as the next potential runner. Community chatter highlights the stock's potential to mirror the moves of other low float bio stocks. Some traders point to the company's expanded R&D collaboration as a possible catalyst.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amidst a debate over its valuation and long-term potential in the quantum computing sector. Bulls cite potential government contracts, big tech partnerships and the company's quantum supremacy as reasons for optimism, while bears point to high valuations and a new 2x short ETF ($QBTZ) as signs of a possible correction. Community members are actively discussing whether this surge is sustainable or a bubble about to burst.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to its recent contract news, which has sparked significant interest in the stock's potential. The community is actively discussing its low float and potential for a substantial run, while also noting the stock's volatility and trading patterns. Some traders believe the stock is undervalued, while others are wary of potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail traders piled into Palisade Bio on Wednesday after the biotech company said it would raise approximately $120 million from an underwritten public offering.The stock soared 52.4% on Wednesday to close at $0.45, marking its best session in more than nine months, and gained another 9.5% in after-hours trading.Palisade will offer approximately 171.4 million shares of its common stock, or its equivalent, at $0.70 per share. The underwriters also have an option to purchase about 25.7 million shares at $0.70 for a period of 45 days. Ladenburg Thalmann &amp; Co. Inc. is leading the process, which is expected to close on October 2.The company further stated that the proceeds from the deal will be used to fund its drug pipeline, targeting autoimmune, inflammatory, and fibrotic conditions.The fresh fundraising follows a series of recent developments on the drug development front. Last month, Palisade reported positive early-stage data from its experimental drug PALI-2108 in the treatment of inflammatory bowel diseases. In a small ulcerative colitis trial, the treatment was found to improve outcomes for all patients, with two patients achieving complete remission. The drug was also found to be safe and well-tolerated in a prior study.Palisade also recently secured regulatory approval in Canada to commence an early-stage trial of PALI-2108 in fibrostenotic Crohn’s disease. The study is expected to kick off later this year and will deliver its first data in early 2026.On Stocktwits, retail sentiment for Palisade Bio was ‘extremely bullish’ amid a 33,300% surge in 24-hour message volume.One user stated that the stock appeared strong in overnight trading and expected it to reach $2 by Thursday. At the same time, another predicted that Palisade Bio could rally further next week following weekend data updates.<stembedurl>https://stocktwits.com/Tazdoc88/message/630728209</stembedurl><stembedurl>https://stocktwits.com/smolcapcat/message/630723724</stembedurl><a href="https://stocktwits.com/symbol/PALI">Palisade Bio’s stock</a> has declined 20.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Palisade Bio’s stock (PALI) has declined 20.6% so far in 2025. (Photo credit: Getty Images)

Palisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains Ahead

The rally came as traders reacted to its $120 million capital raise, aimed at accelerating development of new therapies for autoimmune, inflammatory, and fibrotic diseases.

Equity

Palisade Bio Announces 1-for-15 Reverse Stock Split

Carlsbad,CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), ( Palisade , Palisade Bio or the Company ), a biopharmaceutical company focused on developing and...

Palisade Bio files to sell 3.63M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA Research Report) and Palisade Bio...

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end Formation of Clinical...

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad,CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ( Palisade or the Company ), a biopharmaceutical company focused on developing novel therapeutics for...

Palisade Bio's Corporate Shake-Up Sparks Investor Interest

Palisade Bio (PALI) has released an update. Dive into the latest buzz from the financial world as a renowned company unveils a corporate update tha...

Palisade Bio Provides Corporate Update and Reiterates Guidance

Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision Advancement of PALI-2108 for the treatment of moderate-to-severe...

Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

Carlsbad,CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ( Palisade or the Company ), a biopharmaceutical company focused on developing novel therapeutics for...

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Palisade Bio, Inc.

 Bruce Sands MD, MS

 Palisade Bio, Inc.

 Florian Rieder, MD

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School...

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Palisade Bio Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$2.00
Prev Close	$1.68
Open	$1.84
Dividend Yield	0.00%
50-Day Moving Average	$0.8396
Beta	1.36
Avg. Volume	1.26M
PE Ratio	-0.27

52-Week High	$4.32
52-Week Low	$0.53
Market Capitalization	$15.32M
EPS (Annual)	-$10.19
Price to Book	3.08
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PALI
Palisade Bio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PALI News

PALI Palisade Bio Inc